FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
Get Alerts MRNA Hot Sheet
Join SI Premium – FREE
(Updated - September 17, 2021 3:33 PM EDT)
The FDA voted against recommending a booster of Pfizer's (PFE) Covid vaccine, with just 2 out of 18 voting for approval and the other 16 voting 'no'.
The question asked during the FDA panel was, "Do the safety and effectiveness data from clinical trail C4591001 support approval of Comirnaty booster dose administered at least 6 months after completion of the primary series for use in individuals 16 years of age and older?"
Shares of Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) traded lower throughout the day as the panel discussed the topic. Peer and mRNA vaccine maker Moderna (NASDAQ: MRNA) was also lower. Johnson & Johnson (NYSE: JNJ) was little changed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PMV Pharmaceuticals (PMVP) PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO
- Starbucks (SBUX) announces several leadership changes
- Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of BLA Resubmission of LYMPHIR for Treatment of Adults with R/R Cutaneous T-Cell Lymphoma
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA News, Trader TalkRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!